伏立康唑（UK-109,496）可抑制氟康唑敏感及耐药念珠菌属的生长并改变其形态。
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.
作者信息
Belanger P, Nast C C, Fratti R, Sanati H, Ghannoum M
机构信息
Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California 90509, USA.
出版信息
Antimicrob Agents Chemother. 1997 Aug;41(8):1840-2. doi: 10.1128/AAC.41.8.1840.
Abstract
The effects of voriconazole on the growth, ultrastructure, and leakage of cytoplasmic materials of Candida species were investigated. MIC data showed that voriconazole was more active than fluconazole. Exposure of yeast to voriconazole caused growth inhibition, cell wall thinning, and cell membrane degradation. Neither cell collapse nor release of cytoplasmic materials was observed in the treated cells.
摘要
研究了伏立康唑对念珠菌属的生长、超微结构及细胞质物质渗漏的影响。最低抑菌浓度（MIC）数据表明，伏立康唑比氟康唑活性更强。将酵母暴露于伏立康唑会导致生长抑制、细胞壁变薄及细胞膜降解。在处理过的细胞中未观察到细胞塌陷或细胞质物质释放。
相似文献
1
Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species.伏立康唑（UK-109,496）可抑制氟康唑敏感及耐药念珠菌属的生长并改变其形态。
Antimicrob Agents Chemother. 1997 Aug;41(8):1840-2. doi: 10.1128/AAC.41.8.1840.
2
Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain.伏立康唑和伊曲康唑对来自西班牙的念珠菌属氟康唑敏感及氟康唑耐药临床分离株的体外活性比较
Eur J Clin Microbiol Infect Dis. 1999 Jun;18(6):432-5. doi: 10.1007/s100960050313.
3
Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.伏立康唑对氟康唑敏感和耐药念珠菌分离株的作用：与伊曲康唑和酮康唑相比的体外疗效
J Antimicrob Chemother. 1998 Aug;42(2):253-6. doi: 10.1093/jac/42.2.253.
4
In vitro activity of voriconazole against Candida species isolated in Taiwan.伏立康唑对台湾分离出的念珠菌属的体外活性。
Int J Antimicrob Agents. 2004 Sep;24(3):294-6. doi: 10.1016/j.ijantimicag.2004.01.014.
5
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.两种三唑类抗真菌剂（伏立康唑[UK-109,496]和氟康唑）对念珠菌属的体外研究。
Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.
6
[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].氟康唑、伏立康唑和泊沙康唑对念珠菌属的体外活性
Rev Esp Quimioter. 2003 Jun;16(2):227-32.
7
A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.一种新型三唑类药物伏立康唑（UK-109,496）可阻断白色念珠菌和克鲁斯念珠菌中的甾醇生物合成。
Antimicrob Agents Chemother. 1997 Nov;41(11):2492-6. doi: 10.1128/AAC.41.11.2492.
8
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.伏立康唑（UK-109,496）及其他四种抗真菌药物对394株念珠菌属临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Jan;42(1):161-3. doi: 10.1128/AAC.42.1.161.
9
Activity of voriconazole against Candida albicans and Candida krusei isolated since 1984.自1984年以来伏立康唑对白色念珠菌和克柔念珠菌的活性。
Int J Antimicrob Agents. 2000 Nov;16(3):205-9. doi: 10.1016/s0924-8579(00)00191-6.
10
Effects of voriconazole on Candida glabrata in vitro.
J Antimicrob Chemother. 1999 Jul;44(1):109-12. doi: 10.1093/jac/44.1.109.
引用本文的文献
1
Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.氟康唑和伏立康唑对光滑念珠菌、近平滑念珠菌和罗伊氏乳杆菌生物膜影响的比较研究。
Mycopathologia. 2018 Jun;183(3):499-511. doi: 10.1007/s11046-018-0243-z. Epub 2018 Jan 29.
2
Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.伏立康唑或两性霉素B作为初始治疗，会产生与侵袭性曲霉病预后相关的不同早期血清半乳甘露聚糖趋势。
PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014.
3
Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis.合成芳基喹诺利定衍生物对白色念珠菌、热带念珠菌和近平滑念珠菌具有抗真菌活性。
Ann Clin Microbiol Antimicrob. 2011 Jan 21;10:3. doi: 10.1186/1476-0711-10-3.
4
Growth inhibition and ultrastructural alterations induced by Delta24(25)-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organisms.Delta24(25)-甾醇甲基转移酶抑制剂对念珠菌属分离株（包括非白色念珠菌）诱导的生长抑制及超微结构改变
BMC Microbiol. 2009 Apr 20;9:74. doi: 10.1186/1471-2180-9-74.
5
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.美沙酮治疗患者中伏立康唑与美沙酮在稳态时的药代动力学相互作用。
Antimicrob Agents Chemother. 2007 Jan;51(1):110-8. doi: 10.1128/AAC.00559-06. Epub 2006 Oct 30.
6
Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors.烟曲霉的胆固醇摄取及其对甾醇生物合成抑制剂抗真菌效力的影响。
Antimicrob Agents Chemother. 2005 Feb;49(2):518-24. doi: 10.1128/AAC.49.2.518-524.2005.
7
Serum voriconazole levels following administration via percutaneous jejunostomy tube.经皮空肠造口管给药后的血清伏立康唑水平。
Antimicrob Agents Chemother. 2003 Oct;47(10):3375. doi: 10.1128/AAC.47.10.3375.2003.
8
Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.伏立康唑对一名肝移植受者及人肝微粒体中他克莫司代谢的抑制作用。
Antimicrob Agents Chemother. 2002 Sep;46(9):3091-3. doi: 10.1128/AAC.46.9.3091-3093.2002.
9
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.伏立康唑静脉给药至口服剂量递增方案后的药代动力学及安全性
Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53. doi: 10.1128/AAC.46.8.2546-2553.2002.
10
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.念珠菌生物膜的抗真菌药敏性：两性霉素B脂质制剂和棘白菌素的独特疗效
Antimicrob Agents Chemother. 2002 Jun;46(6):1773-80. doi: 10.1128/AAC.46.6.1773-1780.2002.
本文引用的文献
1
Effects of antineoplastic agents on growth, morphology and metabolism of Torulopsis glabrata.抗肿瘤药物对光滑球拟酵母生长、形态及代谢的影响
Mycopathologia. 1986 Sep;95(3):175-81. doi: 10.1007/BF00437124.
2
Antimycotic effects of octenidine and pirtenidine.
J Antimicrob Chemother. 1990 Feb;25(2):237-45. doi: 10.1093/jac/25.2.237.
Zotero 插件